Press release content from PR Newswire. The AP news staff was not involved in its creation. Asieris and Photocure Expand Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan January 26, 2021 GMT SHANGHAI, Jan. 26, 2021 /PRNewswire/ -- Asieris Pharmaceuticals announced today that the company has entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to exclusively register and commercialize Hexvix® in Mainland China and Taiwan. Hexvix® is a drug that preferentially accumulates in bladder cancer cells, making them glow bright pink during Blue Light Cystoscopy (BLC®). It is expected to meet a strong unmet need in the diagnosis and resection of non-muscle invasive bladder cancer (NMIBC) in Mainland China and Taiwan.